| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Dauricine (0-20 μM, 8 days) suppresses the proliferation of SW620, HCT116, HCT8, and SW480 cells [1]. In HCT116 cells, dauricine (0–20 μM, 12 and 24 hours) triggers G1 phase cell cycle signaling [1]. In HCT116 cells, dauricine (0–20 μM, 36 h) causes the activation of NF-κB signaling [1]. In HCT116 cells, dauricine (0–20 μM, 6 h) causes the activation of NF-κB signaling [1]. and 2 μg/mL, 24 hours) prevents HepG2 and Huh-7 cells from experiencing elevated phosphate glycolysis and oxidative phosphorylation [3]. Dauricine (2 μg/mL, 48 hours) enhances HCC cell lines' apoptosis studies and response to cisplatin. [1]
|
|---|---|
| ln Vivo |
Dauricine (subcutaneous injection, 40 mg/kg, every 2 days for 9 days) suppresses tumor growth in the HCT116 xenograft mouse model [1]. Dauricine (1 or 10 mg/kg, intraperitoneal injection) can ameliorate cognitive impairment, diminish Aβ accumulation and Tau hyperphosphorylation in the 3xTg-Alzheimer's disease mice model [2].
|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: HCT 116 Tested Concentrations: 5, 10, 20 μM Incubation Duration: 36 h Experimental Results: Shows apoptosis The percentage rates ranged from 7.8% to 14.4%, 19.8%, and Sorafenib's proportion [3]. 29.7% at 5, 10 and 20 μM. Increased accumulation of cleaved PARP and caspase3. Western Blot Analysis [1] Cell Types: HCT 116 Tested Concentrations: 5, 10, 20 μM Incubation Duration: 36 hrs (hours) Experimental Results: Inhibition of TNF (0.5 nM)-induced p65 phosphorylation and nuclear translocation. |
| Animal Protocol |
Animal/Disease Models: HCT116 xenograft mouse model [1]
Doses: 40 mg/kg Route of Administration: subcutaneous injection, 2 days each time. 9-day Experimental Results: Colon tumor growth was completely inhibited on the 9th day, with little effect on body weight. |
| References |
|
| Additional Infomation |
Dauricine is a bisbenzylisoquinoline alkaloid resulting from the formal oxidative dimerisation of 4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenol by attachment of the phenolic oxygen of one molecule to the benzene ring of the second (ortho to the phenolic hydroxy group of the latter). It has a role as a plant metabolite. It is a tertiary amino compound, a member of phenols, an aromatic ether, a member of isoquinolines and a bisbenzylisoquinoline alkaloid.
Dauricine has been reported in Nelumbo nucifera, Menispermum canadense, and Menispermum dauricum with data available. |
| Molecular Formula |
C38H44N2O6
|
|---|---|
| Molecular Weight |
624.7658
|
| Exact Mass |
624.319
|
| CAS # |
524-17-4
|
| PubChem CID |
73400
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
712.3±60.0 °C at 760 mmHg
|
| Melting Point |
115ºC
|
| Flash Point |
384.6±32.9 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.601
|
| LogP |
6.61
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
46
|
| Complexity |
933
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)OC)O)OC)OC
|
| InChi Key |
AQASRZOCERRGBL-ROJLCIKYSA-N
|
| InChi Code |
InChI=1S/C38H44N2O6/c1-39-15-13-26-20-35(42-3)37(44-5)22-29(26)31(39)17-24-7-10-28(11-8-24)46-34-19-25(9-12-33(34)41)18-32-30-23-38(45-6)36(43-4)21-27(30)14-16-40(32)2/h7-12,19-23,31-32,41H,13-18H2,1-6H3/t31-,32-/m1/s1
|
| Chemical Name |
4-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-[4-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]phenoxy]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~160.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6006 mL | 8.0029 mL | 16.0059 mL | |
| 5 mM | 0.3201 mL | 1.6006 mL | 3.2012 mL | |
| 10 mM | 0.1601 mL | 0.8003 mL | 1.6006 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
